The 2026 Autumn Budget has been dubbed a holding Budget, offering the Government breathing space while bigger decisions are made. For the NHS, there was little immediate relief and no comprehensive answer to the pressures facing patients and clinicians. But the quieter announcements deserve attention: changes to how government protects spending and assesses investment could prove consequential for health.

A further £190 million was announced for the NHS in England to manage winter and in-year pressures. While welcome, this represents short-term relief rather than an answer to the service’s structural challenges.

The more significant developments may therefore be what comes next, with the Government placing its bigger bets on productivity, prevention and technology.

Can technology deliver the productivity gains?

Perhaps the most significant announcement was an independent review of NHS productivity and AI, led by Mark Bailie, Chief Executive of Compare the Market and a non-executive director of NHS England. Reporting in early 2027, the review will examine how AI and technology can transform patient services and improve productivity, with its findings informing the next Spending Review.

The Budget points to the NHS App, now used by more than 39 million people, and the growing use of AI-supported diagnostics as evidence of technology’s potential. It also allocated £100 million from existing NHS capital funding to accelerate robotic-assisted surgery and announced an AI Challenge Prize focused on frontline healthcare challenges.

Yet these ambitions come against a challenging financial backdrop, with planned NHS capital investment now lower than previously anticipated. The British Medical Association (BMA) was particularly critical of the wider settlement, accusing the Government of “papering over the cracks” in the health service.

Productivity cannot simply mean deploying more technology. Decisions about AI-assisted triage, diagnostics, clinical pathways and automation have implications for professional standards, patient safety, workforce design, medical education and the clinician-patient relationship.

Professional bodies, clinicians and patients must therefore be closely involved as the review develops. The real test will be whether its recommendations deliver meaningful improvements in care, and whether services have the capacity and resources to put them into practice.

Prevention: an opportunity to change direction?

The Budget also signalled a potentially significant shift towards prevention. From the 2027 Spending Review, the Government intends to introduce a ringfenced category of preventative expenditure, potentially strengthening investment in interventions that reduce future demand.

This announcement received a notably positive response from health policy organisations. Siva Anandaciva, Director of Policy, Events and Partnerships at The King’s Fund, described the proposal as having the potential to be “genuinely transformational”, suggesting it could help shift the NHS towards maintaining health rather than primarily treating illness.

The Health Foundation similarly welcomed the move, with Dr Jennifer Dixon highlighting the importance of protecting preventative investment from short-term financial pressures. The organisation has long advocated an approach that recognises the wider economic value of improving population health.

But important questions remain. What will count as prevention? How much funding will be protected? And how will success be measured?

Prevention extends beyond the NHS, encompassing housing, employment, economic security and local public health services. Yet the Budget offered no new settlement for the Public Health Grant, raising questions about the resources available to deliver preventative services locally.

The detail will matter. A ringfence could protect investment that is too often squeezed by immediate pressures, but its impact will depend on what it covers, how accountability is shared and whether it supports coordinated action across services.

A technical change with longer-term consequences

Alongside the proposed protection for preventative spending, the Budget formalised a quieter change to the Treasury’s Green Book: reducing the headline discount rate used in public investment appraisal from 3.5% to 3.0%.

The rate determines how future costs and benefits are valued today. A lower rate gives greater weight to outcomes delivered further into the future. For health organisations, this could strengthen the case for investments whose benefits take time to emerge, including some prevention programmes and improvements to infrastructure.

The implications will depend on each proposal’s costs, benefits and applicable appraisal guidance. The headline reduction should not be assumed to improve every health business case, particularly where specific health discounting arrangements previously applied.

Taken together, the discount-rate change and proposed prevention ringfence could influence both how long-term investment is justified and how spending is protected. Neither guarantees additional funding, but both deserve attention from organisations seeking to shape the next Spending Review.

Wider pressures, competing priorities

There were positive announcements for the wider health and life sciences sector. The Government committed £165 million to a National AI Biosecurity Initiative, including £100 million for a new AI Biosecurity Lab.

Convatec, Vertex Pharmaceuticals and Kindeva also announced investments totalling more than £1 billion, supported by almost £70 million in government grants, alongside plans for regulatory reform to accelerate innovation in medicines and medical devices.

A less prominent measure – the removal of VAT on medicines donated free of charge – also deserves recognition for its potential to support early and expanded access to innovative treatments.

However, these measures cannot disguise the limited immediate commitments to NHS service capacity, workforce pressures or the challenges facing patients and clinicians. The tension between supporting innovation and ensuring services can adopt it remains unresolved.

The bigger decisions are still to come

The Government has outlined its direction for health reform, but many important funding and delivery decisions remain ahead.

For health organisations, engagement needs to reach beyond headline spending commitments. The definitions underpinning preventative expenditure, the evidence used in investment appraisal and the recommendations of the productivity review could all shape which proposals secure support.

The task now is to connect clinical evidence, workforce realities and patient outcomes with the Government’s evolving approach to investment. That means demonstrating not only what an intervention costs today, but when its benefits emerge, who benefits and how those gains can be measured.

The opportunity to influence those decisions is now, while the rules and priorities that will shape future investment are still being developed.

CONTACT US

Let’s talk.

Whether you are navigating health policy reform, engaging policymakers, developing communications strategies or looking to strengthen stakeholder relationships, Grayling Health can help.

Email ross.laird@grayling.com

This article was written by Grayling’s Healthcare expert Ross Laird, and Stuart Carroll, Senior Counsel, Health and Life Sciences.